Bluebird Bio Inc
![Bluebird Bio Inc](https://api.admiralmarkets.com/trade_icons/bright-128/BLUE.png)
Închisă
0.52 -7.14
Rezumat
Modificarea prețului
24h
Minim
0.51
Maxim
0.53
Venit | -72M |
---|---|
Vânzări | 12M |
EPS | -0.66 |
Marjă de profit | -578.849 |
EBITDA | -84M |
Recomandări | Cumpărare |
---|---|
Prognoză pe 12 luni | +686.79 upside |
Următoarele câștiguri | 5 nov. 2024 |
---|
Capitalizare de piață | 5.7M 240M |
---|---|
Deschiderea anterioară | 7.66 |
Închiderea anterioară | 0.52 |
Scor tehnic
By Trading Central
Încredere
Bearish Evidence
Bluebird Bio Inc Grafic
Știri relevante
Comparație
Modificare preț
Bluebird Bio Inc Așteptări
Obiectiv de preț
By TipRanks
686.79% sus
Prognoză pe 12 luni
Medie 4.17 USD 686.79%
Maxim 6 USD
Minim 3 USD
În baza a 10 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBluebird Bio Inc - Dist în ultimele 3 luni.
Date financiare
Cheltuieli de vânzare și administrare
Cheltuieli de exploatare
Profit pre-impozitare
Vânzări
Costul vânzărilor
Profit brut din vânzări
EBITDA
Profit operațional
$
Despre Bluebird Bio Inc
bluebird bio, Inc. is a biotechnology company. The Company focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases and cancer. It develops LentiGlobin for sickle cell disease (SCD) as a one-time treatment for patients with SCD, a hereditary blood disorder resulting from a mutation in the ß-globin gene that causes polymerization of hemoglobin proteins, resulting in abnormal red blood cell function. It builds an integrated product platform with therapeutic in a variety of indications based on its lentiviral gene addition platform, gene editing and cancer immunotherapy capabilities. Its programs in genetic disease include betibeglogene autotemcel; LentiGlobin gene therapy for sickle cell disease (SCD); and elivaldogene autotemcel. Its programs in oncology are focused on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies.